

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Financial Statements

For the Year Ended 31 December 2019

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

31 December 2019

TABLE OF CONTENTS

Directors' Report	1
Auditors Independence Declaration	7
Statement of Profit or Loss and other Comprehensive Income	8
Statement of Financial Position	9
Statement of Changes in Equity	10
Statement of Cash Flows	11
Notes to the Financial Statements	12
Directors Declaration	20
Independent Audit Report	21
Detailed Income Statement	23

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Directors' Report

31 December 2019

The directors present their report of Australasian Gynaecological Endoscopy & Society Limited, together with the financial statements, on the company for the year ended 31 December 2019.

General Information

Directors

The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:

President	Dr Stuart Salfinger
Vice President	Dr Stephen Lyons
Honorary Secretary	Dr Rachel Green
Treasurer	A/Prof Krish Karthigasu
Immediate Past President	Prof Jason Abbott
Ordinary Directors	Dr Fariba Behnia-Willison Dr Kirsten Connan Dr Bassem Gerges Dr Helen Green Dr Martin Ritossa Dr Michael Wynn-Williams
Trainee Member Director	Dr Rachel Collings

Principal activities

The principal activity of the Australasian Gynaecological Endoscopy & Surgery Society Limited during the financial year was the educational advancement of Gynaecological and endoscopic surgery in Australia and New Zealand.

No significant change in the nature of this activity occurred during the year.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Directors' Report

31 December 2019

Information on Directors

Dr Stuart Salfinger

Experience Subspecialist Gynaecologic Oncologist of King Edward Memorial Hospital, Subiaco, WA, St John of God Hospital, Subiaco, WA and Hollywood Private Hospital, Nedlands WA. Certified Gynaecologic Oncologist. Fellow of RANZCOG. Member of RANZCOG. Member of International Gynaecologic Cancer Society. Medical Research Advisory Committee - Ovarian Cancer Australia; Board member and Director Australian Medical Association (WA).

Special Responsibilities Board member, President

Dr Stephen Lyons

Experience BSc (Hons), PhD, MBBS (Hons), FRANZCOG; Visiting Obstetrician & Gynaecologist at Mater Hospital, North Shore Private Hospital, Royal North Shore Hospital, and Gynaecologist at Royal Hospital for Women (Sydney); Member of American Association of Gynaecological Laparoscopists; Editorial Advisory Board Member for Journal of Minimally Invasive Gynaecology; Member of RANZCOG Council (Federal); Ex-Officio Member of RANZCOG NSW Regional Committee.

Special Responsibilities Board Member, Vice President

Prof Jason Abbott

Experience Fellow of RANZCOG, Fellow of RCOG, Doctorate of Philosophy in laparoscopic surgery 2003, Gynaecological Surgeon, Royal Hospital for Women, Sydney Professor Gynaecological Surgery, UNSW, Director Alana Healthcare for Women, Senior Editor JMIG, Associate Editor ANZJOG, Medical Director Endometriosis Australia, Endometriosis Advisory Group Member Department of Health, Chair National Endometriosis Clinical and Scientific Trials (NECST) Network; Chair Expert Endometriosis Working Group (RANZCOG); FIGO Menstrual Disorders Group Member

Special Responsibilities Board member, Immediate Past President

A/Prof Krishnan Karthigasu

Experience MBBS(UWA), FRANZCOG (2002), MRCOG (1999), FRCOG (2011) Clinical Associate Professor, University of Western Australia Specialist Gynaecologist and Head of Dept. Gynaecology Endoscopy, King Edward Memorial Hospital Private Practice Specialist Gynaecological Endoscopic Surgeon, NEDLANDS WA Clinician in fertility, Fertility Specialists South Executive, Anatomy of Complications Workshop Member Gynaecology Practice Improvement Committee KEMH, Member O&G management committee KEMH Examiner and Training Supervisor RANZCOG Past experience- Board member AGES 2005-2009, Chair Training and Accreditation RANZCOG WA, WA RANZCOG college councillor organisation membership- AGES, ASCCP, ISGE, AAGL, WES

Special Responsibilities Board Member, Treasurer

Dr Rachel Green

Experience Fellow of RANZCOG, Director of R Green Medical. Visiting medical officer in Obstetrics and Gynaecology at St Andrews Hospital Ipswich.

Special Responsibilities Board Member, Hon. Secretary

Dr Michael Wynn-Williams

Experience Specialist Gynaecologist, Co-founder and a Director of Eve Health, Private surgical services at the Mater Private, and the Wesley Private Hospitals, Public surgery at the Mater Hospital, Senior Lecturer with the University of Queensland, Fertility treatments through Queensland Fertility Group, Training Supervisor for Australasian Gynaecological Endoscopy & Surgery Society(AGES) two-year training program, helped initiate Persistent Pelvic Pain Clinic at the Mater Hospital, Developed the AGES Laparoscopic Cadaveric Pelvic Anatomy program.

Special Responsibilities Board Member

Dr Fariba Behnia-Willison

Experience Fellow of RANZCOG, Master of Minimally Invasive Surgery Pelvic floor reconstructive surgeon & Endogynaecologist at Flinders Medical Centre Senior lecturer at Flinders University South Australia. Director FBW Gynaecology Plus. Chair of Advisory Board Idatamap Australia Clinical Advisory Board Ashford Hospital

Special Responsibilities Board Member

Dr Kirsten Connan

Experience MBBS (Hon) Fellow of RANZCOG. Founder and Director of Tasmanian O&G Specialists. Visiting Medical Officer Royal Hobart Hospital and Hobart Private Hospital. Hobart Private Hospital Medical Advisory Group. RANZCOG Gender equity and Diversity Working Group Member.

Special Responsibilities Board Member

Dr Bassem Gerges

Experience BSci (Info Sys), MCom (Fin), MBBS (Hons), FRANZCOG, MAdvGynSurg (Deans Medal), AGES Laparoscopic Fellowship (SWAPS), AGES Training Supervisor, RANZCOG Training Supervisor, Honorary Associate Clinical Lecturer at the University of Sydney and Conjoint Lecturer at Western Sydney University, Visiting Medical Officer in Obstetrics & Gynaecology at Blacktown, Norwest Private, Westmead Private and Sydney Adventist Hospitals.

Special Responsibilities Board Member

Dr Helen Green

Experience Subspecialist Gynaecologic Oncologist of Gold University Hospital, Gold Coast Private Hospital, Pindara Private Hospital and John Flynn Hospital. Certified Gynaecologic Oncologist. Fellow of RANZCOG. Member of IGCS. Member of ANZGOG. Member of ASGO. Chair of GCUH HREC Committee. Member of RANZCOG CGO Subcommittee.

Special Responsibilities Board Member

Dr Martin Ritossa

Experience MBBS, Fellow RANZCOG, Gynaecological Surgeon, Divisional Director (Medical) - Northern Adelaide Local Health Network, Deputy Chair SA&NT RANZCOG State Committee, ACHS - Clinical indicator working party chair, Department of Health MBS Gynaecology Implementation Liaison Group, SA Health Gynaecology Advisory Group

Special Responsibilities Board Member

Dr Rachel Collings

Experience Fellow of RANZCOG. AGES Laparoscopic Fellow Gold Coast University Hospital. Member of AGES. Member of ESHRE.

Special Responsibilities Trainee Representative

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Directors' Report

31 December 2019

Information on Directors (continued)

Meetings of Directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the year ended 31 December 2019, and the number of meetings attended by each director were:

	Full Board	
	Held	Attended
Dr Stuart Salfinger	7	7
Dr Stephen Lyons	7	6
Dr Rachel Green	7	6
A/Prof Krish Karthigasu	7	7
Prof Jason Abbott	7	6
Dr Fariba Behnia-Willison	7	7
Dr Kirsten Connan	7	5
Dr Bassem Gerges	7	7
Dr Helen Green	7	7
Dr Martin Ritossa	7	7
Dr Michael Wynn-Williams	7	7
Dr Rachel Collings	7	7

Held: represents the number of meetings held during the time the director held office or was a member of the relevant committee.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Directors' Report

31 December 2019

Business Review

Operating Results

The position of the Australasian Gynaecological Endoscopy & Surgery Society Limited for 2019 is a loss of (\$80,558); (2018: profit \$50,700)

AGES continues to be in a solid financial position, with net assets of \$1.785 million. This is almost totally represented by cash reserves.

The 2019 turnover of the Society was an increase over prior years, however due to the strong accumulated surpluses achieved over previous years you Board budgeted for additional expenditure on specific services and training for members such as a new improved website, free Surgical Performance subscriptions and the introduction of the Train The Trainer educational training workshops. As a result of these initiatives the loss for the 2019 year was both budgeted for and anticipated by the Board.

Your Board will continue to seek initiatives to deliver innovative resources, training and education to the members at minimal fees wherever possible and returning value to the members from the prudent governance of the past Boards. We are able to do so due to the strong financial position of the Society and continuing proactive responsible management.

Dividends paid or declared

The company is not permitted to declare dividends under its constitution.

Other items

Significant Changes in State of Affairs

No significant changes in Australasian Gynaecological Endoscopy & Surgery Society Limited's state of affairs occurred during the financial year.

After balance date events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of Australasian Gynaecological Endoscopy & Surgery Society Limited, the results of those operations or the state of affairs of Australasian Gynaecological Endoscopy & Surgery Society Limited in future financial years.

Future developments

Likely developments in the operations of the Company and the expected results of those operations in future financial years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Company.

Environmental Issues

The Company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a state or territory.

Contributions on winding up

In the event of the company being wound up, ordinary members are required to contribute a maximum of \$10 each. Honorary members are not required to contribute.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 7.

This report is made on behalf of the Board of Directors.

On behalf of the directors



Dr Stuart Salinger

Date : 7-2-2020

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Auditor's Independence Declaration

For the Year Ended 31 December 2019



Tel: +61 7 3237 5999
Fax: +61 7 3221 9227
www.bdo.com.au

Level 10, 12 Creek St
Brisbane QLD 4000
GPO Box 457 Brisbane QLD 4001
Australia

DECLARATION OF INDEPENDENCE BY P A GALLAGHER TO THE DIRECTORS OF AUSTRALASIAN GYNAECOLOGICAL ENDOSCOPY & SURGERY SOCIETY LIMITED

As lead auditor of Australasian Gynaecological Endoscopy & Surgery Society Limited for the year ended 31 December 2019, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in black ink, appearing to read 'P A Gallagher'.

P A Gallagher
Director

BDO Audit Pty Ltd

Brisbane, 7 February 2020

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Statement of Profit or Loss and other Comprehensive Income

For the Year Ended 31 December 2019

	Notes	2019	2018
		\$	\$
Delegate Conference Income		880,402	700,846
Conference Sponsorship Income		965,066	876,349
Membership Income		184,600	173,405
Travelling Fellowship		-	-
Clinical Research Fund		40,000	20,000
AGES Education Training Unit Fees		40,364	40,355
Interest Income		52,998	52,031
Total Revenue		2,163,430	1,862,986
Conference Expenses		(1,618,415)	(1,300,220)
Travelling Fellowship Expenses		-	-
Clinical Research Fund Expenses		(70,000)	(70,000)
Administrative Expenses		(555,573)	(442,066)
Surplus / (Deficit) before income tax expense		(80,558)	50,700
Income Tax Expense		-	-
Surplus / (Deficit) after income tax expense for the year attributable to the members of Australasian Gynaecological Endoscopy & Surgery Society Limited		(80,558)	50,700

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Statement of Financial Position

As at 31 December 2019

	Notes	2019 \$	2018 \$
ASSETS			
Current Assets			
Cash and cash equivalents	2	2,116,957	2,254,503
Trade and other receivables	3	224,037	495,759
Other Assets	4	193,156	158,204
Total Current Assets		2,534,150	2,908,466
Non-Current Assets			
Intangibles	6	-	-
Other Assets	7	16,008	9,508
Total Non-Current Assets		16,008	9,508
TOTAL ASSETS		2,550,158	2,917,974
LIABILITIES			
Current Liabilities			
Trade and other payables	5	699,789	1,004,787
Total Current Liabilities		699,789	1,004,787
Non-Current Liabilities			
Trade and other payables	8	65,636	47,895
Total Non-Current Liabilities		65,636	47,895
TOTAL LIABILITIES		765,425	1,052,682
NET ASSETS		1,784,733	1,865,292
EQUITY			
Retained Surplus	11	1,784,733	1,865,292
TOTAL EQUITY		1,784,733	1,865,292

The above statement of financial position should be read in conjunction with the accompanying notes

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Statement of changes in Equity

For the Year Ended 31 December 2019

2019		Retained Earnings	Total
		\$	\$
Balance at 1 January 2019		1,865,292	1,865,292
Surplus / (Deficit) after income tax expense for the year		(80,559)	(80,559)
Other comprehensive income for the year, net tax		-	-
Total comprehensive income for the year		(80,559)	(80,559)
Balance at 31 December 2019	11	1,784,733	1,784,733

2018		Retained Earnings	Total
		\$	\$
Balance at 1 January 2018		1,814,592	1,814,592
Surplus / (Deficit) after income tax expense for the year		50,700	50,700
Other comprehensive income for the year, net tax		-	-
Total comprehensive income for the year		50,700	50,700
Balance at 31 December 2018	11	1,865,292	1,865,292

The above statement of changes in equity should be read in conjunction with the accompanying notes

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Statement of Cash Flows

For the Year Ended 31 December 2019

	Notes	2019	2018
		\$	\$
Cash flows from Operating Activities			
Current Assets			
Cash receipts in the course of operations		3,088,740	2,627,956
Cash payments in the course of operations		(3,260,921)	(2,515,608)
Interest received		52,998	52,031
GST Received / (Paid)		(18,364)	(33,907)
Net cash from Operating Activities	17	(137,547)	130,472
Cash flows from Investing Activities			
Payments for property, plant and equipment		-	-
Net cash used in Investing Activities		-	-
Cash flows from Financing Activities		-	-
Net cash from Financing Activities		-	-
Net Increase in cash and cash equivalents		(137,547)	130,472
Cash and cash equivalents at the beginning of the financial year		2,254,504	2,124,032
Cash and cash equivalents at the end of the financial year	2	2,116,957	2,254,504

The above statement of cash flows should be read in conjunction with the accompanying notes

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 1 Statement of Significant Accounting Policies

The financial statements cover Australasian Gynaecological Endoscopy & Surgery Society Limited as an individual entity. The financial statements are presented in Australian dollars, which is Australasian Gynaecological Endoscopy & Surgery Society Limited's functional and presentation currency.

Australasian Gynaecological Endoscopy & Surgery Society Limited is a not-for-profit unlisted public company limited by guarantee, incorporated and domiciled in Australia.

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for not-for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 1.

Revenue recognition

Revenue is recognised at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the consolidated entity: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

When payments for membership are received in the current financial year for subscriptions relating to a forthcoming financial year, the income is recognised as a liability, income in advance.

When conference, sponsorship, research grant payments are received in the current financial year for items relating to a forthcoming financial year, the income is recognised as a liability, income in advance.

Sponsorship and research grant income are recognised on an accrual basis.

All revenue is stated net of the amount of goods and services tax (GST).

Income tax

The company was endorsed as a tax exempt entity for income tax purposes on 12 December 2008. The surplus or deficit attributable to members is shown before income tax expense/(benefit).

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 1 Statement of Significant Accounting Policies (continued)

Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Trade and other receivables

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Trade and other payables

These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the Australian Taxation Office. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the Australian Taxation Office, are presented as operating cash flows.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 1 Statement of Significant Accounting Policies (continued)

Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events; management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Estimation of useful lives of assets

The company determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Note 2 Current Assets – cash and cash equivalents

	2019	2018
	\$	\$
Cash on Hand	266,957	418,008
Cash on Hand – USD Account	-	-
Term Deposit	1,850,000	1,836,495
	<u>2,116,957</u>	<u>2,254,503</u>

Note 3 Current assets – trade and other receivables

	2019	2018
	\$	\$
Undeposited Funds	-	-
Trade receivables	224,037	495,759
	<u>224,037</u>	<u>495,759</u>

Note 4 Current assets - other

	2019	2018
	\$	\$
Prepayments	189,756	158,204
Consumable Stock	3,400	-
	<u>193,156</u>	<u>158,204</u>

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 5 Current liabilities – trade and other payables

	2019	2018
	\$	\$
Trade payables	74,687	67,952
GST payable	10,860	41,909
Other payables	8,000	8,000
Membership income in advance	106,364	87,232
Conference income in advance	461,264	771,316
Clinical Research Grant	38,614	28,378
	<u>669,789</u>	<u>1,004,787</u>

Note 6 Non-current assets – Intangibles

	2019	2018
	\$	\$
Website costs – at cost	9,245	9,245
Less: Accumulated depreciation	(9,245)	(9,245)
	<u>-</u>	<u>-</u>

Note 7 Non-current assets – Other assets

	2019	2018
	\$	\$
Prepayments – Non-Current	16,008	9,508
	<u>16,008</u>	<u>9,508</u>

Note 8 Non-current liabilities

	2019	2018
	\$	\$
Membership in Advance – Non-Current	65,636	47,895
	<u>65,636</u>	<u>47,895</u>

Note 9 Number of employees

There were no employees in 2019 (2018: Nil).

Note 10 Auditors' Remuneration

	2019	2018
	\$	\$
BDO	8,000	8,000
	<u>8,000</u>	<u>8,000</u>

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 11 Equity – retained surpluses

	2019	2018
	\$	\$
Retained surpluses at the beginning of the financial year	1,865,292	1,814,592
(Deficit) / Surplus after income tax expense for the year	<u>(80,559)</u>	<u>50,700</u>
	<u>1,784,733</u>	<u>1,865,292</u>

Note 12 Financial instruments

Financial risk management objectives

The company's activities do not expose it to material financial risks, with only liquidity risk, foreign currency risk and Interest rate risk being needed to be actively managed.

Credit risk

The maximum exposure to credit risk at balance date to recognised financial assets excluding the value of any collateral or other securities is the carrying amount of those assets, net of any provisions for doubtful debts, as disclosed in the balance sheet and notes to the financial statements.

Market risk

Foreign currency risk

The company does not currently hold any assets in foreign currency.

Price risk

The company is not exposed to any significant price risk.

Interest rate risk

The Company's exposure to market risk for changes in interest rates relates primarily to cash holdings. Interest rates applicable are determined by the company's financial institution and are broadly based on variable market interest rates.

Liquidity Risk

The company manages liquidity risk by maintaining adequate cash reserves by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Maturity analysis

The company's exposure to interest rate risk, which is the risk that a financial instruments value will fluctuate as a result of changes in market interest rates and classes of financial assets and financial liabilities, is as follows:

	Interest Rate Risk						Maturity Analysis				Total	
	Non-Interest bearing		Floating Interest Rate		Fixed Interest Rate		Maturing within 1 Year		Maturing 1 to 5 Year			
	2019	2018	2019	2018	2019	2018	2019	2018	2019	2018	2019	2018
	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Financial Assets:												
Cash and cash equivalents	-	-	266,957	418,008	1,850,000	1,836,495	1,850,000	1,836,495	-	-	2,116,957	2,254,503
Total Financial Assets	-	-	266,957	418,008	1,850,000	1,836,495	1,850,000	1,836,495	-	-	2,116,957	2,254,503
Financial Liabilities:												
Bank loans and overdrafts	-	-	-	-	-	-	-	-	-	-	-	-
Total Financial Liabilities	-	-	-	-	-	-	-	-	-	-	-	-

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 13 Contingent liabilities

The company had no contingent liabilities as at 31 December 2019 and 31 December 2018.

Note 14 Commitments

The company had no commitments for expenditure as at 31 December 2019 and 31 December 2018.

Note 15 Related party transactions

The directors transact with the Company for membership and conference services on the same basis as all other members of the company, except for life members who do not pay subscriptions and directors who receive accommodation at conferences during engagement in directors' meetings. President's travel expenses were paid for the purpose of promoting AGES meetings internationally during the year of \$8,192 (2018: \$7,261).

Note 16 Events after the reporting period

No matter or circumstance has arisen since 31 December 2019 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

Note 17 Reconciliation of surplus after income tax to net cash from operating activities

	2019	2018
	\$	\$
(Deficit)/ Surplus after income tax expense for the year	(80,559)	50,700
Adjustments for:		
Depreciation	-	-
Write off – Fixed Assets	-	-
Change in operating assets and liabilities:		
Decrease / (Increase) in trade and other receivables	271,722	(379,538)
(Increase) in prepayments	(41,453)	(93,590)
(Decrease) / Increase in trade and other payables	(20,466)	82,537
(Decrease) / Increase in other deferred Income	(266,791)	470,363
	<u>(137,547)</u>	<u>130,472</u>

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Notes to the Financial Statements

For the Year Ended 31 December 2019

Note 18 General information

The registered office and principal place of business are:

Registered office

Suite 7, 63 Macgregor Terrace

Bardon QLD 4065

Principal place of business

Suite 7, 63 Macgregor Terrace

Bardon QLD 4056

A description of the nature of the company's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 10th February 2020. The directors have the power to amend and reissue the financial statements.

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Directors Declaration

For the Year Ended 31 December 2019


The Directors have determined that the company is a reporting entity and that this general purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The Directors of the company declare that:

1. The Financial statements and notes as set out on pages 8 -19 , are in accordance with the Corporations Act 2001 and;
 - (a) Comply with Accounting standards as described in Note 1 to the financial statements and the Corporations Regulations 2001; and
 - (b) Give a true and fair view of the financial position as at 31 December 2019 and its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements
2. In the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the board of directors

On behalf of the directors



Dr Stuart Salfinger
Director

Date: 7-2-2020

INDEPENDENT AUDITOR'S REPORT

To the members of Australasian Gynaecological Endoscopy & Surgery Society Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Australasian Gynaecological Endoscopy & Surgery Society Limited (the Company), which comprises the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the directors' declaration.

In our opinion the accompanying financial report of Australasian Gynaecological Endoscopy & Surgery Society Limited, is in accordance with the *Corporations Act 2001*, including:

- (i) Giving a true and fair view of the Company's financial position as at 31 December 2019 and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Company in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The directors are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the annual report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at: http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO Audit Pty Ltd



P A Gallagher
Director

Brisbane, 7 February 2020

Australasian Gynaecological Endoscopy & Surgery Society Limited

ABN 33 075 573 367

Detailed Income Statement

For the Year Ended 31 December 2019

	2019	2018
Income	\$	\$
Conference Income	864,433	688,919
Conference Sponsorship Income	965,066	876,349
Membership Income	184,600	173,405
Clinical Research Fund	40,000	20,000
AGES Education Training Unit Fees	40,364	40,355
Interest Income	52,998	52,031
Other Income	15,969	11,927
Total Income	2,163,430	1,862,986
Expenses		
AGM & Board Expenses	1,501	2,010
Board Strategic plan costs	40,868	-
Accounting	38,585	27,889
Auditing	8,000	8,000
Awards	6,835	11,022
Bad Debt	-	132
Bank charges	2,072	1,007
Conference Expenses	1,618,416	1,297,812
Clinical Research Fund	70,000	70,000
Credit Card surcharge fee	3,126	1,662
Consultancy Fees	-	1,500
Depreciation	-	-
Education Training Unit		
• Education Expenses	46,653	21,074
• Video Expenses	13,030	44,840
ESAC Expenses	2,009	1,775
Equipment	-	-
Freight and Cartage	3,908	1,813
Gifts	2,752	583
Incidentals	51	183
Insurance	8,400	8,557
Journal Expenses & Publications	39,755	42,152
Legal Expenses	-	1,000
Marketing	19,053	19,495
Membership Expenses	11,171	9,491
Secretariat Costs		
• Administration Costs	80,331	73,140
• Society Management	121,530	114,705
Software Expenses	4,879	3,438
Sponsorship Expenses	15,512	14,056
Surgical Performance	28,800	7,200
Telephone & Fax	3,885	4,330
Travel	8,192	7,261
Website	44,675	16,159
Total Expenses	2,243,989	1,812,286
Operating Revenue	-80,559	50,700